Regulation of hematopoiesis by ribosomal protein paralogs
核糖体蛋白旁系同源物对造血的调节
基本信息
- 批准号:10333363
- 负责人:
- 金额:$ 56.1万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2014
- 资助国家:美国
- 起止时间:2014-07-18 至 2025-01-31
- 项目状态:未结题
- 来源:
- 关键词:AblationAcute Myelocytic LeukemiaAddressAdultAnemiaAttenuatedB-LymphocytesBindingBiogenesisBiological ProcessBiologyDependenceDevelopmentDiseaseDisease ProgressionDistalDysmyelopoietic SyndromesEmbryoErythroidFunctional disorderFutureGene ExpressionGene ProteinsHealthHematologic NeoplasmsHematopoiesisHematopoieticHematopoietic Stem Cell TransplantationHematopoietic stem cellsHumanHydroxyeicosatetraenoic AcidsIn VitroKnowledgeLigandsLinkLipidsLipoxygenaseMalignant NeoplasmsMediatingMediator of activation proteinMessenger RNAMetabolismMyelogenousPathway interactionsPlayPositioning AttributeProcessProtein BiosynthesisRNARNA BindingRNA SplicingRNA StabilityRegulationRepressionRibosomal ProteinsRibosomesRoleSignal TransductionSpecificityStem Cell DevelopmentT-Cell DevelopmentTestingTherapeuticTissuesTranslationsZebrafishantagonistarachidonateattenuationcancer immunotherapycell behaviorcombinatorialexperimental studyfallsfatty acid oxidationfetalhematopoietic stem cell emergencehematopoietic stem cell self-renewalhnRNP A1immune checkpoint blockadeinsightlink proteinloss of functionmouse modelnovelnovel strategiesnovel therapeutic interventionparalogous geneprogenitorprotein functionreconstitutionstem cell biologystem cell function
项目摘要
PROJECT SUMMARY/ABSTRACT
Ribosomal proteins (RP) are increasingly understood to play crucial regulatory roles in development and disease;
however, the way they do so remains unclear. The potential modes of RP action fall into two classes: effects on
the ribosome itself or extraribosomal functions carried out while physically separate from the ribosome.
Traditional loss-of-function approaches to address RP function fail to distinguish these modes of action because
most RP are essential for ribosome biogenesis and/or function and so ablation of such RP genes attenuates
both modes of action. Consequently, an unequivocal determination of the contributions of extraribosomal RP
functions to biological processes remains a critical gap in knowledge. Importantly, we have identified an RP,
Rpl22, which is not required for ribosome biogenesis or function, but nevertheless plays critical, selective roles
in hematopoiesis. Rpl22 not only regulates hematopoietic stem cell (HSC) emergence in the embryo but also
regulates adult HSC function, as well as more distal stages of hematopoiesis including B and T lymphocyte
development. The basis for the selective requirement for Rpl22 in particular hematopoietic processes remains
unclear; however, we have recently determined that the capacity of Rpl22 to regulate fetal HSC emergence is
dependent upon its physical association with hnRNP-A1, which can regulate translation. Moreover, hnRNP-A1
selectively associates with Rpl22 molecules that are physically separate from the ribosome. Consequently, we
have an unprecedented opportunity to investigate the importance of the extraribosomal function of Rpl22 in
hematopoiesis. We hypothesize that Rpl22 regulates hematopoiesis chiefly through its extraribosomal activity,
by associating with hnRNP-A1, and regulating the translation, splicing and possibly the stability of RNA targets
that differ depending on the cellular context. Indeed, while Rpl22 controls fetal HSC emergence by regulating
the expression of Smad1, Rpl22 controls adult HSC behavior by regulating the expression of a lipoxygenase
(Alox12), which generates lipid species that activate PPARd, a master regulator of fatty acid oxidation (FAO). As
FAO has been shown to regulate HSC self-renewal, we hypothesize that Rpl22 regulates Alox12 signaling to
maintain HSCs. In this proposal, we will test these hypotheses in two aims. Aim 1 seeks to determine how the
Rpl22/hnRNP-A1 axis exerts its functions in controlling HSC biology, and identify the specific Rpl22-regulated
fetal and adult hematopoietic processes that depend on Rpl22 association with hnRNP-A1. Aim2 focuses on
investigating the mechanism and role of downstream Alox12-driven FAO pathways through which Rpl22 controls
adult HSC function. In pursing these studies, we will integrate cutting edge structural analysis with the unique
strengths of zebrafish and a variety of novel mouse models, and verify core findings in human progenitors.
Together, these studies will provide the first insight into the novel, extraribosomal “moonlighting” functions
through which RP regulate biological processes, and may reveal the basis for the tissue specificity of Rpl22-
dependence displayed by particular hematopoietic processes.
PROJECT SUMMARY/ABSTRACT
Ribosomal proteins (RP) are increasingly understood to play crucial regulatory roles in development and disease;
however, the way they do so remains unclear. The potential modes of RP action fall into two classes: effects on
the ribosome itself or extraribosomal functions carried out while physically separate from the ribosome.
Traditional loss-of-function approaches to address RP function fail to distinguish these modes of action because
most RP are essential for ribosome biogenesis and/or function and so ablation of such RP genes attenuates
both modes of action. Consequently, an unequivocal determination of the contributions of extraribosomal RP
functions to biological processes remains a critical gap in knowledge. Importantly, we have identified an RP,
Rpl22, which is not required for ribosome biogenesis or function, but nevertheless plays critical, selective roles
in hematopoiesis. Rpl22 not only regulates hematopoietic stem cell (HSC) emergence in the embryo but also
regulates adult HSC function, as well as more distal stages of hematopoiesis including B and T lymphocyte
development. The basis for the selective requirement for Rpl22 in particular hematopoietic processes remains
unclear; however, we have recently determined that the capacity of Rpl22 to regulate fetal HSC emergence is
dependent upon its physical association with hnRNP-A1, which can regulate translation. Moreover, hnRNP-A1
selectively associates with Rpl22 molecules that are physically separate from the ribosome. Consequently, we
have an unprecedented opportunity to investigate the importance of the extraribosomal function of Rpl22 in
hematopoiesis. We hypothesize that Rpl22 regulates hematopoiesis chiefly through its extraribosomal activity,
by associating with hnRNP-A1, and regulating the translation, splicing and possibly the stability of RNA targets
that differ depending on the cellular context. Indeed, while Rpl22 controls fetal HSC emergence by regulating
the expression of Smad1, Rpl22 controls adult HSC behavior by regulating the expression of a lipoxygenase
(Alox12), which generates lipid species that activate PPARd, a master regulator of fatty acid oxidation (FAO). As
FAO has been shown to regulate HSC self-renewal, we hypothesize that Rpl22 regulates Alox12 signaling to
maintain HSCs. In this proposal, we will test these hypotheses in two aims. Aim 1 seeks to determine how the
Rpl22/hnRNP-A1 axis exerts its functions in controlling HSC biology, and identify the specific Rpl22-regulated
fetal and adult hematopoietic processes that depend on Rpl22 association with hnRNP-A1. Aim2 focuses on
investigating the mechanism and role of downstream Alox12-driven FAO pathways through which Rpl22 controls
adult HSC function. In pursing these studies, we will integrate cutting edge structural analysis with the unique
strengths of zebrafish and a variety of novel mouse models, and verify core findings in human progenitors.
Together, these studies will provide the first insight into the novel, extraribosomal “moonlighting” functions
through which RP regulate biological processes, and may reveal the basis for the tissue specificity of Rpl22-
dependence displayed by particular hematopoietic processes.
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
DAVID L. WIEST其他文献
DAVID L. WIEST的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('DAVID L. WIEST', 18)}}的其他基金
Functional Analysis of Variants Underlying T Cell Defects
T 细胞缺陷变异的功能分析
- 批准号:
10024573 - 财政年份:2020
- 资助金额:
$ 56.1万 - 项目类别:
Functional Analysis of Variants Underlying T Cell Defects
T 细胞缺陷变异的功能分析
- 批准号:
10462634 - 财政年份:2020
- 资助金额:
$ 56.1万 - 项目类别:
ThymUS 2020 International Conference on Lymphopoiesis
ThymUS 2020 国际淋巴细胞生成会议
- 批准号:
9913243 - 财政年份:2020
- 资助金额:
$ 56.1万 - 项目类别:
Functional Analysis of Variants Underlying T Cell Defects
T 细胞缺陷变异的功能分析
- 批准号:
10256631 - 财政年份:2020
- 资助金额:
$ 56.1万 - 项目类别:
The ThymUS 2016 International Conference on Lymphopoiesis
ThymUS 2016 国际淋巴细胞生成会议
- 批准号:
8986580 - 财政年份:2016
- 资助金额:
$ 56.1万 - 项目类别:
Regulation of Hematopoiesis by Ribosomal Protein Paralogs
核糖体蛋白旁系同源物对造血的调节
- 批准号:
8816656 - 财政年份:2015
- 资助金额:
$ 56.1万 - 项目类别:
Molecular Basis for gamma/delta T Lineage Specification
gamma/delta T 谱系规范的分子基础
- 批准号:
8608275 - 财政年份:2014
- 资助金额:
$ 56.1万 - 项目类别:
Regulation of Hematopoiesis By Ribosomal Protein Paralogs
核糖体蛋白旁系同源物对造血的调节
- 批准号:
8880580 - 财政年份:2014
- 资助金额:
$ 56.1万 - 项目类别:
Regulation of hematopoiesis by ribosomal protein paralogs
核糖体蛋白旁系同源物对造血的调节
- 批准号:
10548846 - 财政年份:2014
- 资助金额:
$ 56.1万 - 项目类别:
相似海外基金
Computing analysis of leukemic stem cell dynamics in acute myelocytic leukemia
急性粒细胞白血病白血病干细胞动力学的计算分析
- 批准号:
19K08356 - 财政年份:2019
- 资助金额:
$ 56.1万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Generation of immunotoxins with super-targeting mAb in the acute myelocytic leukemia
在急性髓细胞白血病中使用超靶向单克隆抗体产生免疫毒素
- 批准号:
23501309 - 财政年份:2011
- 资助金额:
$ 56.1万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
DETERMINANTS OF RESPONSE OF ACUTE MYELOCYTIC LEUKEMIA
急性粒细胞白血病反应的决定因素
- 批准号:
3556971 - 财政年份:1980
- 资助金额:
$ 56.1万 - 项目类别:
DETERMINANTS OF RESPONSE OF ACUTE MYELOCYTIC LEUKEMIA
急性粒细胞白血病反应的决定因素
- 批准号:
3556968 - 财政年份:1980
- 资助金额:
$ 56.1万 - 项目类别:
ERADICATION OF ACUTE MYELOCYTIC LEUKEMIA CELLS BY MAB THERAPY
通过 MAB 疗法根除急性粒细胞白血病细胞
- 批准号:
3889304 - 财政年份:
- 资助金额:
$ 56.1万 - 项目类别: